Rpo LLC Buys Shares of 20,937 AbCellera Biologics Inc. (NASDAQ:ABCL)

Rpo LLC purchased a new position in shares of AbCellera Biologics Inc. (NASDAQ:ABCL) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 20,937 shares of the company’s stock, valued at approximately $61,000. AbCellera Biologics makes up approximately 0.1% of Rpo LLC’s portfolio, making the stock its 26th biggest position.

Other hedge funds have also made changes to their positions in the company. DKM Wealth Management Inc. acquired a new stake in AbCellera Biologics in the 4th quarter worth approximately $29,000. State of New Jersey Common Pension Fund D bought a new position in shares of AbCellera Biologics in the fourth quarter valued at approximately $36,000. Diametric Capital LP bought a new position in shares of AbCellera Biologics in the fourth quarter valued at approximately $53,000. IMG Wealth Management Inc. acquired a new stake in shares of AbCellera Biologics in the fourth quarter worth $56,000. Finally, Raymond James Financial Inc. acquired a new position in AbCellera Biologics in the 4th quarter valued at $57,000. Institutional investors and hedge funds own 61.42% of the company’s stock.

Analyst Upgrades and Downgrades

ABCL has been the subject of a number of research analyst reports. Stifel Nicolaus cut their target price on shares of AbCellera Biologics from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Friday, February 28th. Benchmark reissued a “hold” rating on shares of AbCellera Biologics in a research report on Monday, March 3rd. Finally, KeyCorp lowered their target price on AbCellera Biologics from $5.00 to $4.00 and set an “overweight” rating on the stock in a report on Wednesday, January 8th.

AbCellera Biologics Price Performance

NASDAQ:ABCL opened at $2.22 on Thursday. AbCellera Biologics Inc. has a one year low of $2.02 and a one year high of $4.75. The company has a fifty day moving average price of $2.79 and a 200 day moving average price of $2.81. The stock has a market cap of $661.53 million, a P/E ratio of -3.64 and a beta of 0.45.

About AbCellera Biologics

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.